| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/30/2001 | WO2001062758A1 Pteridine compounds for the treatment of psoriasis |
| 08/30/2001 | WO2001062757A1 Novel compounds |
| 08/30/2001 | WO2001062756A1 Pyridinylimidazoles |
| 08/30/2001 | WO2001062750A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 08/30/2001 | WO2001062742A1 Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
| 08/30/2001 | WO2001062737A2 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 08/30/2001 | WO2001062736A1 Aryl fused azapolycyclic compounds |
| 08/30/2001 | WO2001062733A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | WO2001062729A1 Novel compounds |
| 08/30/2001 | WO2001062728A1 Novel compounds |
| 08/30/2001 | WO2001062726A2 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 08/30/2001 | WO2001062721A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062718A1 Benzamide derivative and use thereof |
| 08/30/2001 | WO2001062714A1 Novel phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062713A1 Novel phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062712A1 (2s)-aminoindan derivatives, a process for their preparation and their use as selective dopamine d3 ligands |
| 08/30/2001 | WO2001062706A1 Aminoadamantane derivatives as therapeutic agents |
| 08/30/2001 | WO2001062705A2 Aminoalcohol derivatives |
| 08/30/2001 | WO2001062704A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | WO2001062297A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | WO2001062290A2 Methods and compositions for improving sleep |
| 08/30/2001 | WO2001062285A1 Use of il-18 inhibitors |
| 08/30/2001 | WO2001062284A2 Novel method for down-regulation of amyloid |
| 08/30/2001 | WO2001062277A1 Treatment for peripheral sensory neuropathy |
| 08/30/2001 | WO2001062257A2 Bupropion metabolites and methods of their synthesis and use |
| 08/30/2001 | WO2001062254A1 Patches containing buprenorphine hydrochloride |
| 08/30/2001 | WO2001062253A1 Compositions and methods for treatment of epilepsy |
| 08/30/2001 | WO2001062250A1 Thiazolium compounds and treatments of disorders associated with protein aging |
| 08/30/2001 | WO2001062249A1 Use of pramipexole for the treatment of addictive disorders |
| 08/30/2001 | WO2001062246A1 Method for treating neurodegeneration |
| 08/30/2001 | WO2001062236A2 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 08/30/2001 | WO2001062233A2 Adenosine receptor modulators |
| 08/30/2001 | WO2001026705A3 A dual adhesive transdermal drug delivery system |
| 08/30/2001 | WO2001012606A3 Tetrahydroquinoline derivatives having retinoid-like biological activity |
| 08/30/2001 | WO2001012236A3 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 08/30/2001 | WO2001012195A3 Use of morphine derivatives as medicaments for the treatment of neuropathic problems |
| 08/30/2001 | WO2001010900A3 Globular assembly of amyloid beta protein and uses thereof |
| 08/30/2001 | WO2001010457A3 Pharmaceutical compositions containing tripeptides |
| 08/30/2001 | WO2001010430A3 Use of estrogen compounds for prevention and treatment of ischemic damage |
| 08/30/2001 | WO2001010378A3 Controlled release from copolymers of acrylic or methacrylic acid/l-dopa, acrylic or methacrylic acid/l-$g(a)-methyl dopa, acrylic or methacrylic acid/carbidopa and their combinations |
| 08/30/2001 | WO2000073269A3 Nicotine receptor ligands |
| 08/30/2001 | WO2000040733A9 Human cyclic nucleotide pdes |
| 08/30/2001 | US20010018530 Alzheimer's and Parkinson disease |
| 08/30/2001 | US20010018522 Neuropeptide y receptor ligand |
| 08/30/2001 | US20010018451 Raloxifene, tamoxifen |
| 08/30/2001 | US20010018447 Il-8 receptor antagonists |
| 08/30/2001 | US20010018444 Tropane-derivatives, their preparation and use |
| 08/30/2001 | US20010018438 Nervous system disorders; psychological disorders |
| 08/30/2001 | US20010018434 Administering an antiestrogen compound |
| 08/30/2001 | US20010018429 Neurotransmitter |
| 08/30/2001 | US20010018415 Treating cholinergic controlled secretions including excessive sweating, lacrimation and mucus secretion by administering Botulinum toxin type A |
| 08/30/2001 | US20010018198 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same |
| 08/30/2001 | US20010018071 Oral 2-methyl-thieno-benzodiazepine formulation |
| 08/30/2001 | US20010018053 Methods for treating disease states comprising administration of low levels of antibodies |
| 08/30/2001 | CA2683009A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2401226A1 Amino pyrazole derivatives useful for the treatment of obesity and other disorders |
| 08/30/2001 | CA2401219A1 Vertebrate globin |
| 08/30/2001 | CA2401113A1 Transporters and ion channels |
| 08/30/2001 | CA2401036A1 Pyridinylimidazoles |
| 08/30/2001 | CA2401013A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 08/30/2001 | CA2400838A1 Novel method for down-regulation of amyloid |
| 08/30/2001 | CA2400831A1 Estrogen receptor beta variants and methods of detection thereof |
| 08/30/2001 | CA2400823A1 Method for inhibiting angiogenesis using molecules that enhance plasmin formation or prolong plasmin activity |
| 08/30/2001 | CA2400708A1 Methods and compositions for improving sleep |
| 08/30/2001 | CA2400694A1 Thiazolium compounds and treatments of disorders associated with protein aging |
| 08/30/2001 | CA2400491A1 Compositions and methods for treatment of epilepsy |
| 08/30/2001 | CA2400485A1 Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof |
| 08/30/2001 | CA2400435A1 Novel compounds |
| 08/30/2001 | CA2400434A1 Novel compounds |
| 08/30/2001 | CA2400293A1 Novel compounds |
| 08/30/2001 | CA2400099A1 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 08/30/2001 | CA2399442A1 New drug combinations |
| 08/30/2001 | CA2399298A1 Use of il-18 inhibitors |
| 08/30/2001 | CA2398275A1 Human polynucleotides, polypeptides, and antibodies |
| 08/30/2001 | CA2397874A1 Use of pramipexole for the treatment of addictive disorders |
| 08/30/2001 | CA2397705A1 Compounds related to or derived from gfr.alpha.4 and their use |
| 08/30/2001 | CA2397234A1 Novel use of phenylheteroalkylamine derivatives |
| 08/30/2001 | CA2396960A1 Novel use of phenylheteroalkylamine derivatives |
| 08/29/2001 | EP1127894A1 Method of diagnosis of transmissible spongiform encephalopathy (TSE) |
| 08/29/2001 | EP1127882A1 Tetrazole compounds as thyroid receptor ligands |
| 08/29/2001 | EP1127878A1 3,4 - substituted pyrazoles for the treatment of inflammation |
| 08/29/2001 | EP1127871A1 New esters derived from substituted phenyl-cyclohexyl compounds |
| 08/29/2001 | EP1127577A2 Ligand for the c-kit receptor and methods of use thereof |
| 08/29/2001 | EP1127572A2 Use of flavones for treating cycloxygenase-2 mediated diseases |
| 08/29/2001 | EP1127571A1 Use of sertraline to treat post traumatic stress disorder |
| 08/29/2001 | EP1127136A1 Delivery of superoxide dismutase to neuronal cells |
| 08/29/2001 | EP1127123A2 Cell surface glycoproteins |
| 08/29/2001 | EP1127119A1 Compounds and methods for modulating claudin-mediated functions |
| 08/29/2001 | EP1127109A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases |
| 08/29/2001 | EP1127071A1 Compounds with growth hormone releasing properties |
| 08/29/2001 | EP1127069A2 Biological materials and methods useful in the diagnosis and treatment of prion diseases |
| 08/29/2001 | EP1127058A1 Pyrazolopyridine derivatives as selective cox-2 inhibitors |
| 08/29/2001 | EP1127052A1 Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| 08/29/2001 | EP1127045A2 Use of triphenylbutene derivatives for the treatment of neurological disorders |
| 08/29/2001 | EP1126882A2 Stable preparations with hyperforin |
| 08/29/2001 | EP1126865A2 Methods and compositions for treating or preventing peripheral neuropathies |
| 08/29/2001 | EP1126853A1 Controlled delivery of antidepressants |
| 08/29/2001 | EP1126852A1 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 08/29/2001 | EP1126849A1 Heterocyclic potassium channel inhibitors |
| 08/29/2001 | EP1126846A1 Use of a nicotine receptor agonist in the treatment of obsessive compulsive disorder |